BioNTech (Germany) Performance
| 22UA Stock | EUR 115.10 5.20 4.73% |
BioNTech has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioNTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNTech is expected to be smaller as well. BioNTech SE right now shows a risk of 3.15%. Please confirm BioNTech SE downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if BioNTech SE will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BioNTech may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 1.2 B | |
| Total Cashflows From Investing Activities | -566.1 M |
BioNTech |
BioNTech Relative Risk vs. Return Landscape
If you would invest 11,000 in BioNTech SE on September 14, 2024 and sell it today you would earn a total of 510.00 from holding BioNTech SE or generate 4.64% return on investment over 90 days. BioNTech SE is generating 0.1198% of daily returns assuming 3.1497% volatility of returns over the 90 days investment horizon. Simply put, 28% of all stocks have less volatile historical return distribution than BioNTech, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioNTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNTech SE, and traders can use it to determine the average amount a BioNTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.038
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | 22UA | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.15 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average BioNTech is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNTech by adding it to a well-diversified portfolio.
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | 0.76 | |||
| Return On Asset | 0.43 | |||
| Profit Margin | 0.56 % | |||
| Operating Margin | 0.68 % | |||
| Current Valuation | 29.68 B | |||
| Shares Outstanding | 242.68 M | |||
| Price To Earning | 45.99 X | |||
| Price To Book | 2.31 X | |||
| Price To Sales | 2.19 X | |||
| Revenue | 18.98 B | |||
| EBITDA | 15.13 B | |||
| Cash And Equivalents | 914.9 M | |||
| Cash Per Share | 3.75 X | |||
| Total Debt | 171.6 M | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | 76.45 X | |||
| Cash Flow From Operations | 889.7 M | |||
| Earnings Per Share | 38.32 X | |||
| Total Asset | 15.83 B | |||
About BioNTech Performance
By analyzing BioNTech's fundamental ratios, stakeholders can gain valuable insights into BioNTech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioNTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people.Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNTech SE had very high historical volatility over the last 90 days | |
| About 64.0% of the company shares are owned by insiders or employees |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |